表紙
市場調査レポート

Salix Pharmaceuticals Ltd.の製品パイプライン分析

Salix Pharmaceuticals Ltd. - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 207943
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
Salix Pharmaceuticals Ltd.の製品パイプライン分析 Salix Pharmaceuticals Ltd. - Product Pipeline Review - 2014
出版日: 2014年05月30日 ページ情報: 英文 45 Pages
概要

Salix Pharmaceuticals Ltd.は特殊医薬品企業で、消化器疾患の予防および治療用の処方薬を開発、販売しています。

当レポートでは、Salix Pharmaceuticals Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Salix Pharmaceuticals Ltd.の基本情報

Salix Pharmaceuticals Ltd.の概要

  • 主要情報
  • 企業情報

Salix Pharmaceuticals Ltd.:R&Dの概要

  • 主な治療範囲

Salix Pharmaceuticals Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Salix Pharmaceuticals Ltd.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ

Salix Pharmaceuticals Ltd.:薬剤プロファイル

  • budesonide
  • methylnaltrexone bromide
  • rifaximin
  • budesonide ER
  • RHB-106
  • SAN-300

Salix Pharmaceuticals Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Salix Pharmaceuticals Ltd.:最近のパイプライン動向

Salix Pharmaceuticals Ltd.:休止中のプロジェクト

Salix Pharmaceuticals Ltd.:企業発表

Salix Pharmaceuticals Ltd.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC04880CDB

Global Markets Direct's, 'Salix Pharmaceuticals Ltd. - Product Pipeline Review - 2014', provides an overview of the Salix Pharmaceuticals Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Salix Pharmaceuticals Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Salix Pharmaceuticals Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Salix Pharmaceuticals Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Salix Pharmaceuticals Ltd.'s pipeline products

Reasons to buy

  • Evaluate Salix Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Salix Pharmaceuticals Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Salix Pharmaceuticals Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Salix Pharmaceuticals Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Salix Pharmaceuticals Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Salix Pharmaceuticals Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Salix Pharmaceuticals Ltd. Snapshot
    • Salix Pharmaceuticals Ltd. Overview
    • Key Information
    • Key Facts
  • Salix Pharmaceuticals Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Salix Pharmaceuticals Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Salix Pharmaceuticals Ltd. - Pipeline Products Glance
    • Salix Pharmaceuticals Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Salix Pharmaceuticals Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
  • Salix Pharmaceuticals Ltd. - Drug Profiles
    • budesonide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methylnaltrexone bromide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rifaximin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • budesonide ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RHB-106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAN-300
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Salix Pharmaceuticals Ltd. - Pipeline Analysis
    • Salix Pharmaceuticals Ltd. - Pipeline Products by Target
    • Salix Pharmaceuticals Ltd. - Pipeline Products by Route of Administration
    • Salix Pharmaceuticals Ltd. - Pipeline Products by Molecule Type
    • Salix Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action
  • Salix Pharmaceuticals Ltd. - Recent Pipeline Updates
  • Salix Pharmaceuticals Ltd. - Dormant Projects
  • Salix Pharmaceuticals Ltd. - Company Statement
  • Salix Pharmaceuticals Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Salix Pharmaceuticals Ltd., Key Information
  • Salix Pharmaceuticals Ltd., Key Facts
  • Salix Pharmaceuticals Ltd. - Pipeline by Indication, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014
  • Salix Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014
  • Salix Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2014
  • Salix Pharmaceuticals Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
  • Salix Pharmaceuticals Ltd. - Pre-Registration, 2014
  • Salix Pharmaceuticals Ltd. - Phase III, 2014
  • Salix Pharmaceuticals Ltd. - Phase II, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Target, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2014
  • Salix Pharmaceuticals Ltd. - Recent Pipeline Updates, 2014
  • Salix Pharmaceuticals Ltd. - Dormant Developmental Projects,2014
  • Salix Pharmaceuticals Ltd., Subsidiaries

List of Figures

  • Salix Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014
  • Salix Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014
  • Salix Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • Salix Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top